Advanced Biomed Inc. SEC filings document a Nevada emerging growth company with common stock listed on Nasdaq under ADVB. The filings identify the issuer’s biotechnology focus in precision medicine and advanced diagnostics and record material events affecting its capital structure, listed security and corporate organization.
Recent 8-K and amended 8-K filings cover securities purchase agreements, an equity line of credit, a short-term loan agreement, share issuances, the 1-for-20 reverse stock split and Nasdaq minimum-bid-price correspondence. They also document director and officer changes, material definitive agreements, completed acquisition or disposition activity, amendments to charter documents, and other formal disclosures tied to governance, financing and shareholder rights.
Advanced Biomed Inc. reported net income of $5,982,078 for the nine months ended March 31, 2026, driven mainly by a one-time gain of $7,346,684 from selling its Hong Kong subsidiary and related clinical operations. From continuing operations, the company earned $6,254,557 over nine months but posted a quarterly loss of $488,942, reflecting ongoing R&D and administrative costs.
Cash from continuing operations was $2,602,697 at March 31, 2026, with net cash used in operating activities of $1,363,675. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on new funding, including a January 2026 private placement raising $248,000 and an equity line facility of up to $25,000,000. The company executed a 1‑for‑20 reverse stock split and had 1,382,133 shares outstanding as of March 31, 2026.
Advanced Biomed Inc. completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited by issuing 270,000 shares of its common stock at $4.00 per share, for an estimated consideration of $1,080,000. The shares were issued under Section 4(a)(2) of the Securities Act.
The company is undertaking a strategic pivot from life sciences to artificial intelligence development. In connection with this change, former CEO and chairman Yi Lu entered into a mutual separation, receiving 39,999 shares of common stock as severance, and Xiaomin Chen was appointed as the new Chief Executive Officer, director and Chairman of the Board with compensation of $12,000 per month.
Advanced Biomed Inc. entered into an unsecured Loan Agreement with Jie Wang under which the lender provided a US$600,000 short-term loan. The loan carries a 10% annual interest rate, runs for six months from the disbursement date, and may be extended once for an additional six months by mutual written agreement.
The company must repay the full US$600,000 principal plus accrued interest on or before the maturity date but can prepay at any time without penalty, with partial prepayments applied first to interest and then principal. Advanced Biomed plans to use the loan proceeds for operations, and the agreement is governed by New York law.
Advanced Biomed Inc. entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, which provides AI-powered financial verification and audit solutions. The seller will receive 270,000 shares of Advanced Biomed common stock, valued at $4.00 per share, for an estimated total of $1,080,000.
The acquisition is conditioned on completing financial and legal due diligence of Acellent and obtaining all required regulatory approvals, so the transaction has not yet closed.
Advanced Biomed Inc. reported leadership changes effective March 25, 2026. Steven I-Fang Cheng resigned as both a member of the Board of Directors and as Chief Technology Officer. The company stated that his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the Board, following a recommendation from the Nominating Committee, appointed Chief Financial Officer Mingze Yin as a director. The company disclosed that Mr. Yin has no family relationships with other leaders, no special arrangements leading to his appointment, and no related-party transactions requiring disclosure.
Advanced Biomed Inc. reported that Nasdaq has determined the company regained compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company implemented a reverse stock split completed on February 20, 2026, after shareholders approved the action on January 12, 2026.
Following the reverse split, the company’s common stock maintained a closing bid of at least $1.00 per share, satisfying Nasdaq’s rule. As a result, Advanced Biomed’s stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor under Listing Rule 5815(d)(4)(A).
Advanced Biomed Inc. implemented a 1-for-20 reverse stock split of its common stock, effective at the open of trading on February 20, 2026, to consolidate every 20 issued and outstanding shares into 1 share with the same par value.
The capital structure change does not alter the number of authorized shares and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement. After the reverse split, total issued and outstanding common shares change from 27,290,710 to approximately 1,364,536, while the stock continues trading on the Nasdaq Capital Market under the symbol ADVB.
Advanced Biomed Inc. reported net income of $6.47M for the six months ended December 31, 2025, a sharp improvement from a prior-year loss. This turnaround was driven almost entirely by a $7.35M gain on selling its Hong Kong subsidiary and related China operations, which are now classified as discontinued.
From continuing operations the company generated income of $6.74M, while discontinued operations produced a loss of $0.27M. Operating expenses remained modest at $0.79M over six months, reflecting a lean cost base focused on research and development and general and administrative activities.
Despite the reported profit, Advanced Biomed used $1.12M of cash in operating activities and ended the period with cash of $2.60M. Total assets were $10.85M and total liabilities fell to $1.37M, leaving stockholders’ equity of $9.48M, largely helped by the deconsolidation gain.
Management disclosed that the positive earnings are mainly one-time and that recurring operations still consume cash, leading to “substantial doubt” about the company’s ability to continue as a going concern. To support liquidity, Advanced Biomed highlighted its prior IPO and a $25M equity line of credit agreement with an institutional investor, as well as subsequent share issuances in January 2026.
Advanced Biomed Inc. filed an amended current report describing share issuance tied to a previously disclosed equity line of credit. The company has an agreement with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. for an equity line of up to $25,000,000 in common stock.
On January 30, 2026, Advanced Biomed issued 1,650,710 shares of common stock to the investor as a commitment fee under the agreement, with an aggregate value of $500,000 at the time of issuance. These shares were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act of 1933.
Advanced Biomed Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors on January 28, 2026, to issue and sell 4,000,000 shares of common stock at $0.062 per share, for total proceeds of $248,000.
The transaction closed and the shares were issued on January 29, 2026. The shares were sold in a private placement relying on exemptions from U.S. registration under Section 4(a)(2) of the Securities Act and Regulation S.